Pelabresib and Ruxolitinib combo for myelofibrosis in Japan
Treatments studied
Part of Blood & lymphatic clinical trials.
This study tests adding a new drug (pelabresib) to the standard treatment (ruxolitinib) for Japanese people with myelofibrosis. The goal is to see if the combination helps control symptoms like an enlarged spleen.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of myelofibrosis (primary or after another blood disorder).
- Your doctor says you are at intermediate-1, intermediate-2, or high risk.
- You are already taking ruxolitinib (5 to 25 mg twice daily) for at least 8 weeks.
- Your spleen is enlarged (felt or seen on scan).
- Your platelet count is at least 100,000 per microliter of blood (without medication or transfusion to raise it).
- You have fewer than 5% blasts (immature cells) in your blood.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (pelabresib and ruxolitinib) for people with myelofibrosis whose spleen is enlarged and who have bothersome symptoms. It aims to see if adding pelabresib to standard care helps control the disease better.
This trial tests a combination of two medications, ropeginterferon alfa-2b and ruxolitinib, for people with myelofibrosis whose spleen has not shrunk enough or has grown back while on ruxolitinib. The goal is to see if adding the newer drug can improve outcomes.
This trial tests whether adding abemaciclib to ongoing ruxolitinib can better control myelofibrosis in people who are not getting enough benefit from ruxolitinib alone. It is designed to see safety and response in a specific group with intermediate-2 or high-risk disease and ongoing symptoms or enlarged spleen.
This trial tests an experimental drug called PMD-026 for people with myelofibrosis that has not responded well to a JAK inhibitor (like ruxolitinib). The goal is to see if PMD-026 can help reduce symptoms and spleen size.
This trial tests a new combination of two drugs, ruxolitinib and ulixertinib, for people with myelofibrosis whose disease is not fully controlled by ruxolitinib alone. The goal is to see if adding ulixertinib can improve spleen enlargement, symptoms, or bone marrow changes.
This trial tests whether adding TL-895 to ruxolitinib can improve outcomes in adults with myelofibrosis. It focuses on people who are not getting enough benefit from ruxolitinib or who need treatment as part of the study.
Hear when a new Primary Myelofibrosis (PMF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.